@TigerBuford

Retained Recruiter 🦴 Advocate for early stage orthopedic companies

[@TigerBuford @TigerBuford]

Stop watching the orthopedic industry from the sidelines— lead with daily intelligence that is read by 6,136 of your most successful peers.

Subscribe here at $1/day - https://t.co/Z8VtvPnmgh

[@TigerBuford @TigerBuford]

Agency is the real prize.
https://t.co/QCgpAIThtw

[@TigerBuford @TigerBuford]

Agency is the real prize.

Not status.

Not the title.

Not the salary line that shrinks every year while the work stays the same.

We all want the same thing:
the ability to decide where we live,
who we work with,
what constraints we accept,
and which ones we refuse.

Do I have to fill out that form?
Sit in that meeting?
Fly coach?
Be in the office on days that make no sense?
Work for someone who doesn’t even understand the craft?

Most people in their 40s and 50s finally admit it:
they want out of the rat race.
Not retirement.
Ownership.I’ve spent more than a decade building my own.
It’s hard.
But the downside of trying has never been smaller,
and the upside has never been larger.

The internet, the tools, the intelligence available right now—
this is the best moment in history to start something of your own.

Start it on the side while the paycheck still lands.
Nights and weekends are not for Netflix.
They’re the only free leverage most people still own.

Two weeks ago I built a full plan with a partner.
We killed it the moment we saw the juice wasn’t worth the squeeze.
Cost: a little time.
Lesson: permanent.
You can run that experiment every two weeks if you want.When you own the thing:
you choose the city,
the people,
the equity,
the constraints.

Seed capital still hunts good ideas.
The barrier is no longer money or access.
It’s the decision to begin.

Agency isn’t given.
It’s taken—one small experiment at a time.

Go get yours.

--------------END------------

[@TigerBuford @TigerBuford]

Delphi just created a 3D visualization of my mind.

Check it out. https://t.co/weIqDt8LK9

[@TigerBuford @TigerBuford]

The Strategy Behind the DePuy X-PAC Acquisition
https://t.co/CSDVtnJJwK

[@TigerBuford @TigerBuford]

@LSK65_H 911

[@TigerBuford @TigerBuford]

Within seconds… TIGER ON-DEMAND anonymously answers your questions about the orthopedic industry. You will tap into everything that I know about our industry.

Try it now while its still FREE

https://t.co/Vl0uxKLoTf

[@TigerBuford @TigerBuford]

The Great Unbundling of Orthopedics Has Begun

https://t.co/cBgz6NJU4N

[@TigerBuford @TigerBuford]

How to torch $300M building a surgical robot company.

https://t.co/wagL2pOHSt

[@TigerBuford @TigerBuford]

[Tiger’s Weekly Intel] – M&A, Handheld Robotics, and 3D Biomimetic Implants Drive the Shift to ASC-Focused Outpatient Care

https://t.co/gUMgeGgX9W

[@TigerBuford @TigerBuford]

@MrBeast 10,000,000

[@TigerBuford @TigerBuford]

@elonmusk leave CA like I did...

[@TigerBuford @TigerBuford]

Maybe @SteveHiltonx can save California.

[@TigerBuford @TigerBuford]

The “KOL Shortcut” is Dead in 2026
---------
I remember the “Good Old Days.” In that era, the blueprint for an orthopedic startup was as predictable as a Texas sunset. You had a spark of an idea for a slightly better pedicle screw or a marginally smoother hip stem.

You’d find a heavy-hitting Key Opinion Leader (KOL), spend a few weekends in a cadaver lab, freeze the design, and waltz through the FDA.

The KOL didn’t just design the product; they were your built-in revenue engine. They’d call down to the hospital purchasing department and say, “I’m switching to this. Order ten trays.” And just like that, you had early traction. The surgeon was the king, the hospital was a “doctor-run hotel,” and product choice was a matter of professional preference.

Fast forward to 2026. If you’re still pitching that “KOL-first” playbook to investors, you aren’t just old-fashioned—you’re a liability.

The Death of the “Designer Surgeon” Era
------------
The fundamental power dynamic in orthopedics has undergone a seismic shift. We have moved from a Clinical Preference model to an Economic Necessity model.
Today, over 70% of surgeons are employees of hospital systems or massive private equity-backed groups. The “Golden Handcuffs” are real. When a surgeon is an employee, they lose the unilateral power to dictate which implants cross the threshold of the OR. They are now part of a supply chain, and the supply chain is governed by people who care more about “Total Cost of Care” than the “feel” of a rasp.

The $3 Million Math Problem
-----------

Lucky subscribers can read the full story on OrthoStreams - https://t.co/DgkcTnFIVm

[@TigerBuford @TigerBuford]

GLP-1s > Robots,

Root cause fixes are usually more effective than downstream invasive treatments.

From biology's perspective, GLP-1 agonists like semaglutide hit the real villain in orthopedics: metabolic chaos. They slash chronic inflammation, tame insulin resistance, and starve the fat-fueled oxidative storm that chews up cartilage years before surgery's even on the table. That’s not treatment—it’s prevention, rewiring the body so joints don’t need rescuing.

Robotic surgery?

A slick Band-Aid. It nails alignment, trims recovery time a hair, but the data's lukewarm—higher satisfaction in some trials, sure, yet no clear long-term edge over conventional cuts. Biology shrugs at precision gadgets; it cares about stopping the damage upstream.

GLP-1 doesn't just fix the knee—it keeps the whole system from breaking in the first place.

Your thought ?

[@TigerBuford @TigerBuford]

One word - What's the most interesting thing you've seen today in New Orleans at #aaos2026 ?

[@TigerBuford @TigerBuford]

The Tiger Dashboard – Mar 2026

Sharing the best monthly Orthopedic industry DASHBOARD in the ortho industry to the lucky OrthoStreams Subscribers ($1/day) – no-ads, no bias, just my thoughts with exclusive predictions, trends, recent deals, funding intel, public performance breakdowns, hot startups, and struggling companies.

Quick Overview of Detailed Sections:
General Trends in Ortho
M&A Predictions (Future)
M&A Recent
Funding Trends and Recent
IPO Predictions
Public Company Performance
Startups I Like
Struggling and Zombie Public Companies

Buckle up, here we go. #AAOS2026

https://t.co/zpiMAv17lT

[@TigerBuford @TigerBuford]

Your quick startup guide for New Orleans #aaos2026

https://t.co/aHtZCOETxw

[@TigerBuford @TigerBuford]

A few thoughts on non-competes in Orthopedics

​Disclaimer: I am not an attorney. This is not legal advice. These are just observations​

Individuals transition jobs in orthopedics daily without issue, but non-compete agreements can complicate things.

Here’s a breakdown.

1. Non-Competes for Non-Sales Roles (R&D, Marketing, Ops, Clinical, Regulatory, etc.)

Broad non-competes are often unenforceable. Courts prioritize an individual’s right to earn a living in their expertise. For example, some agreements include absurdly restrictive language like:

“[You cannot work on] any product, process, technology, machine, invention, or service of any person or organization other than your current employer… which is similar to, resembles, competes with, or is intended to resemble or compete with a product… I have worked on or about which I was knowledgeable during the last 24 months…”

Such clauses rarely hold up. Companies may intimidate exiting employees, claiming they can’t join a competitor. This is often a tactic, not a reflection of enforceable law. If a company truly valued you, they’d have invested in your growth.

In rare lawsuits, broad non-competes (e.g., “all spine”) are often narrowed (e.g., “stand-alone cages”).

Key points:

New Employer’s Stance: Your new employer (Company B) is usually comfortable with your non-compete from Company A. Smaller companies might fear legal action from larger ones, but this is uncommon.

Role Adjustment: Company B can tweak your role to align outside the non-compete’s scope, if needed.

Exit Gracefully: Leave Company A professionally, assisting with project handoffs and transitions.

Legal Notices: Expect a letter from Company A reminding you to protect trade secrets and honor the non-compete. File it away.

Compensation for Non-Competes: Courts often require that you were compensated (cash, stock, RSUs) for signing the non-compete, as it restricts your rights.

Indemnification: In rare cases, if you or Company B are concerned about legal risks, Company B may indemnify you or adjust your role/title to avoid conflicts.

2. Non-Competes for Sales Roles....

Subscribers ($1/day) get full access to this article and 4,000 others - https://t.co/G0PeGk4li6

[@TigerBuford @TigerBuford]

⚫️ JPM 2026: Why "Boring" is the New Breakthrough in Orthopedics

JPM 2026: From "Recovery" to "Execution"

The "growth at all costs" era is officially dead. The vibe at the 44th Annual J.P. Morgan Healthcare Conference was one of cautious optimism. The industry has pivoted from scrambling for procedure volume recovery to a disciplined focus on operating margins, supply chain stability, and execution.

If 2025 was about stabilization, 2026 is about the "Boring Breakthrough"—where success isn't defined by sci-fi concepts, but by workflow efficiency and profitability.

The Big 3 Trends

1. The "Agentic AI" Era We’ve moved past AI that merely analyzes data to AI that acts.

The Shift: From "Smart Implants" to "Workflow Automation."

The News: Tech that drafts surgical plans for approval and automates back-office revenue cycles.

The Takeaway: If your tech adds administrative burden, it’s dead on arrival. The winning value prop for 2026 is removing friction for ASC staff and surgeons.

2. The ASC "Land Grab" is Structural The migration to ASCs is no longer a trend; it’s the default reality.

The Shift: Capital equipment must fit 400-square-foot ORs. "ASC-ready" (modular, instrument-free) is the new standard.

The News: Commercial models are evolving toward subscription-based placements and risk-sharing agreements.

The Takeaway: Efficiency is the new moat. If you can’t help an ASC turn a room over 10 minutes faster, you aren't competitive.

3. M&A: The Return of the "Bolt-On" Mega-mergers were absent. The checkbooks are open, but only for specific problems.

The Shift: "Tuck-in" acquisitions ($500M - $3B range) to plug portfolio gaps.

The News:Smith+Nephew acquired Integrity Orthopaedics ($450M) to fix their rotator cuff gap.

Medtronic launched a "growth committee" targeting mid-sized deals.

The Takeaway: Startups with single, high-growth products (especially in sports med/extremities) are prime targets. Platforms are buying products, not just revenue.

The Big 4: Speed Round....

Those lucky Subscribers can read the full article on OrthoStreams here - https://t.co/KGiq6Z1I4a